10-Q: Scientific Industries Sells Genie Division, Reports Q2 Loss

Scientific Industries, Inc. reported a wider net loss for Q2 2025 and announced the sale of its Genie Division assets for up to $11.1 million, while also completing a $1.55 million private placement.

Summary

• Net loss for the three months ended June 30, 2025, widened to $1,522,700 from $1,283,600 in the prior year period.
• Revenues for the three months ended June 30, 2025, decreased by 12.0% to $2,329,900, primarily due to lower sales in both Benchtop Laboratory Equipment and Bioprocessing Systems segments.
• Gross profit percentage declined to 43.8% for the quarter, down from 48.8% in the prior year, mainly due to increased material costs from tariffs and fixed overhead.
• For the six months ended June 30, 2025, net loss slightly improved to $3,302,200 from $3,335,200 in the prior year, despite a 7.7% revenue decrease to $4,736,400.
• The company completed a private placement on April 18, 2025, raising $1,550,000 through the issuance of common stock and warrants.
• Subsequent to the quarter, on August 7, 2025, the company entered an agreement to sell substantially all assets of its Genie Division for $9,600,000 cash, plus a potential earn-out of up to $1,500,000.
• Cash and cash equivalents increased to $891,400 as of June 30, 2025, from $587,900 at December 31, 2024, largely due to financing activities.

Sentiment

Score: 3

Explanation: The company reported declining revenues and widening losses for the quarter, alongside a significant increase in cash burn from operations. While a capital raise improved the cash position, it came with dilution. The subsequent sale of a core operating division indicates a major strategic shift, likely driven by operational challenges, and introduces significant uncertainty about the company's future revenue streams and profitability. The overall picture is negative, reflecting ongoing operational difficulties and a shrinking business.

Positives

• Net cash provided by financing activities significantly increased to $1,452,200 for the six months ended June 30, 2025, from $645,700 in the prior year, improving the cash position.
• General and administrative expenses decreased by 8.1% for the three months and 13.8% for the six months ended June 30, 2025, primarily due to a reduction in force in the Bioprocessing Systems Operations.
• Net loss for the six months ended June 30, 2025, slightly narrowed to $3,302,200 compared to $3,335,200 in the prior year.
• The sale of the Genie Division assets for up to $11.1 million provides a significant cash infusion and strategic focus.

Negatives

• Revenues decreased by 12.0% for the three months and 7.7% for the six months ended June 30, 2025, compared to the prior year periods.
• Net loss widened for the three months ended June 30, 2025, to $1,522,700 from $1,283,600.
• Gross profit percentage declined to 43.8% for the quarter and 43.0% for the six months, primarily due to increased material costs from tariffs and fixed overhead.
• Net cash used in operating activities increased to $2,762,900 for the six months ended June 30, 2025, indicating higher cash burn from operations.
• Investment securities significantly decreased from $1,985,000 at December 31, 2024, to $390,900 at June 30, 2025.
• Shareholders' equity decreased to $7,924,200 at June 30, 2025, from $9,119,400 at December 31, 2024.

Risks

• Uncertainty related to the global trade war impacting sales of Genie brand products.
• Customer delays in finalizing orders and requirements for products not yet available in the Bioprocessing Systems Operations.
• Increased material costs due to tariffs, particularly for Torbal OEM products.
• Dependence on a single customer, which accounted for 10% or more of total revenue for the periods reported.
• The company maintains a full valuation allowance of $12,365,400 against its consolidated net deferred tax asset, indicating uncertainty about future profitability to utilize these assets.
• The success of the asset sale and the company's ability to perform under the supply and transition services agreements are crucial for realizing the full purchase price and earn-out.

Future Outlook

The company's forward-looking statements indicate that actual future events could differ materially from assumptions due to factors such as product demand, market acceptance, marketing strategy success, expansion efforts, competition impact, adverse economic conditions, and other uncontrollable business factors. The company does not undertake to publicly update these statements.

Management Comments

• The decrease in revenue for the three months ended June 30, 2025, was primarily due to a decrease of $175,700 in Benchtop Laboratory Equipment Operations, resulting from headwinds created by uncertainty related to the global trade war, and a $141,700 decrease in Bioprocessing Systems Operations revenue due to customer delays in finalizing orders and requirements for products not yet available.
• The decrease in general and administrative expenses is due primarily to decreased employee-related costs associated with a reduction in force in the Bioprocessing Systems Operations during the second quarter of fiscal 2024.
• The increase in selling expenses is due primarily to increased sales and marketing costs incurred by the Bioprocessing Systems Operations.
• The increase in research and development expenses for the three months ended June 30, 2025, is due primarily to increased research and development expenditures in the Bioprocessing Systems Operations related to DOTS new products.
• The decrease in research and development expenses for the six months ended June 30, 2025, is due primarily to the reduction of research and development expenditures in the Benchtop Laboratory Equipment Operations due to completion of the VIVID Workstation product development.

Industry Context

The company operates in the laboratory equipment and bioprocessing sectors, which are sensitive to research funding and global trade conditions. The reported revenue declines, particularly in the Bioprocessing Systems segment due to 'customer delays' and 'products not yet available,' suggest challenges in product commercialization or market readiness. The impact of 'global trade war' on Benchtop Laboratory Equipment sales indicates broader macroeconomic pressures affecting the industry. The divestiture of the Genie Division may reflect a strategic pivot or a response to competitive pressures and operational inefficiencies within that segment.

Management Changes

Legal Proceedings

• None The company is not aware of any contingent legal liabilities that should be reflected in the consolidated financial statements as of June 30, 2025, and December 31, 2024.

Related Party Transactions

• $48,000 paid to Mr. John Nicols, a Director of the Company, for consulting services to the Bioprocessing Systems segment during the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Dilution from recent common stock and warrant issuances. Decreased shareholders' equity. Uncertainty regarding future profitability and strategic direction following the asset sale.
• Employees: Reduction in force in the Bioprocessing Systems Operations in Q2 2024. Voluntary Salary/Compensation Waiver Program offered. Employees in the Genie Division will be impacted by the asset sale.
• Customers: Potential impact on customers of the Genie Division due to the change in ownership and transition services. Delays in product availability for Bioprocessing Systems customers.
• Creditors: Decreased total assets and shareholders' equity, though total liabilities also decreased. The cash infusion from the asset sale could improve liquidity.

Next Steps

• Supply products and provide transition services to Troemner, LLC under the Asset Purchase Agreement for the Genie Division for at least six months, renewable for 3-month periods up to a total of twelve months.
• Continue research and development efforts in the Bioprocessing Systems Operations related to DOTS new products.

Key Dates

Recommendation

The company is experiencing significant revenue declines across both its core segments and continues to report net losses, indicating a challenging operational environment. The gross profit margin is also deteriorating due to cost pressures. While a recent capital raise improved the cash position, it came at the cost of shareholder dilution. Most notably, the subsequent agreement to sell substantially all assets of its Benchtop Laboratory Equipment Operations (Genie Division) signals a major strategic divestiture, likely due to underperformance or a need for capital. This move significantly shrinks the company's operational footprint and introduces considerable uncertainty about its future revenue base and long-term viability, especially given the ongoing losses in the remaining Bioprocessing segment. For a seasoned investor, these factors suggest a deteriorating business outlook and a high degree of risk, warranting a 'sell' recommendation.

Keywords

Scientific Industries, SCND, Laboratory Equipment, Bioprocessing, SEC Filing, 10-Q, Financial Results, Asset Sale, Private Placement, Genie Division, Torbal, DOTS, Bioprocessing Systems, Benchtop Laboratory Equipment